Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Recruiting
Phase 2
Interventional Study
AML, Adult
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 88 (estimated)
- Sponsor
- ETH Zurich · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selec…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* Patient with refractory or relapsed AML according to ELN2022 criteria.
* Age 18-70 years.
* Considered to be eligible for intensive chemotherapy.
* Written informed consent.
Exclusion criteria
* Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomoni…
Contacts